EP Patent

EP2609912A1 — Pharmaceutical combination of fingolimod and nabiximols

Assigned to Deva Holding AS · Expires 2013-07-03 · 13y expired

What this patent protects

This invention is related to single unit formulation of fingolimod or pharmaceutically acceptable salts thereof in combination with nabiximols mostly composed of cannabidiol (CBD) type compound or derivative thereof and tetrahydrocannabinol (THC) type compound or derivative there…

USPTO Abstract

This invention is related to single unit formulation of fingolimod or pharmaceutically acceptable salts thereof in combination with nabiximols mostly composed of cannabidiol (CBD) type compound or derivative thereof and tetrahydrocannabinol (THC) type compound or derivative thereof in treatment of multiple sclerosis.

Drugs covered by this patent

fingolimod-lauryl-sulfate (FINGOLIMOD LAURYL SULFATE)

Patent Metadata

Patent number: EP2609912A1
Jurisdiction: EP
Classification: —
Expires: 2013-07-03
Drug substance claim: No
Drug product claim: No
Assignee: Deva Holding AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.